Viking Therapeutics, Inc. (NASDAQ:VKTX) is one of the best biotech stocks with high potential. H.C. Wainwright analyst Joseph ...
Viking offers asymmetric upside in GLP-1 drugs with positive trial data, strong cash, and buyout potential despite biotech ...
Prosper Junior Bakiny has positions in Eli Lilly and Viking Therapeutics. The Motley Fool recommends Viking Therapeutics. The ...
Zacks Investment Research on MSN
NVO, OMER Ink $2.1B Zaltenibart Deal to Bolster Rare Disease Portfolio
Novo Nordisk NVO and Omeros Corporation OMER have announced the signing of a definitive asset purchase and license agreement ...
10d
Why Viking Therapeutics (VKTX) Is Up 15.1% After Acquisition Buzz and Analyst Focus on Its Pipeline
Recent analyst commentary has emphasized Viking Therapeutics' advanced clinical programs in the obesity and metabolic disease space, spotlighting the company as an independent player in a ...
Viking Therapeutics, Inc. (NASDAQ:VKTX) is one of the Oversold Growth Stocks to Buy According to Analysts. On September 22, ...
Hansoh Pharma grants Merck global rights to develop and commercialize HS-10535 for weight loss. William Blair maintains Viking Therapeutics as a top 2025 pick, citing VK2735’s potential in obesity ...
Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Viking Therapeutics Inc (Symbol: VKTX), where a total of 16,897 contracts have traded so ...
Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Riot Platforms Inc (Symbol: RIOT), where a total of 263,138 contracts have traded so far, ...
Strong demand for Mounjaro and Zepbound is expected to power LLY's Q3 growth, as both drugs deepen U.S. and global market ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback